$265,316,226

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to PARATEK PHARMACEUTICALS, INC

biotechactiveONGOING · MOD OF 2019 CONTRACT

WORK BEGAN2019-12-18·LATEST ACTION2026-03-02·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50120C00001_7505_-NONE-_-NONE-

Award description

ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Latest obligation on a 2019 antibiotic contract for treating a biothreat indication, with work continuing through 2029.

Sub-sectors

antibiotic-developmentbiodefensepharma-procurement

Why this matters

Biodefense pharmaceutical development ensures U.S. medical countermeasures against potential biological threats; this 10-year program reflects sustained strategic investment.

Supply-chain signal

Paratek's antibiotic manufacturing and API supply chains are critical to biodefense readiness; sustained funding signals government commitment to domestic pharmaceutical capacity.

U.S.–China competition angle

Antibiotic development is a strategic vulnerability; China dominates global API production, making U.S. biodefense pharma independence a national security priority.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-19. Cost: $0.003055.

Period of performance

Start

2019-12-18

End

2029-12-17

Status

activein 1266 days

Recipient

PARATEK PHARMACEUTICALS, INC

UEI D5KEFN62CJ97

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50120C00001_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.